Visceral fat endocannabinoid production rose with diabetes, not obesity alone
Visceral fat endocannabinoid overproduction is associated with insulin resistance and tissue dysfunction in mice and humans.
AI Summary
This study asked whether visceral adipose tissue (VAT) produces more endocannabinoids when metabolism is disrupted, and compared VAT with subcutaneous adipose tissue (SAT). Researchers measured production from ex vivo tissue samples from obese mice and people with obesity, including people with and without type 2 diabetes; they also used receptor-deficient mice and tissue gene-expression analyses. In human samples, 2-arachidonoylglycerol (2-AG) was the predominant endocannabinoid, and VAT produced 1.9 times as much as SAT. Obesity alone was not associated with a significant increase in secretion.
VAT from people with type 2 diabetes produced more 2-AG and anandamide (AEA) than control samples, while SAT was largely unchanged. VAT AEA production was also associated with measures of chronic and fasting blood glucose. The authors interpret these findings as evidence that insulin resistance and metabolic dysfunction, rather than excess fat alone, are linked to VAT endocannabinoid overproduction. Because this was an ex vivo and tissue-analysis study, it cannot establish that endocannabinoids cause diabetes or show whether targeting this signaling would improve health; this is an abstract-based summary, not a review of the full paper.
💡 Key Findings
📄
Original Abstract
Related Research
Similar Studies
More Endocannabinoid research papers you might find interesting.
Meta-analysis finds shared endocannabinoid gene changes across myopathies
Small biomarker analysis finds no significant changes after 10 HBOT sessions
Rat study finds mixed behavioral and biological effects of WIN under chronic…
Explore More Research
Stay informed about the latest cannabis science.